Distinct transcriptional and prognostic impacts of TERT promoter mutations C228T and C250T in papillary thyroid carcinoma

in Endocrine-Related Cancer
Authors:
Vicente Rodrigues Marczyk Thyroid Unit, Endocrine division, Hospital de Clínicas de Porto Alegre (HCPA), Brazil
Medical School, Universidade Federal do Rio Grande do Sul (UFRGS), Brazil

Search for other papers by Vicente Rodrigues Marczyk in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0001-7005-722X
,
Ana Luiza Maia Thyroid Unit, Endocrine division, Hospital de Clínicas de Porto Alegre (HCPA), Brazil
Medical School, Universidade Federal do Rio Grande do Sul (UFRGS), Brazil

Search for other papers by Ana Luiza Maia in
Current site
Google Scholar
PubMed
Close
, and
Iuri Martin Goemann Thyroid Unit, Endocrine division, Hospital de Clínicas de Porto Alegre (HCPA), Brazil
Medical School, Universidade Federal do Rio Grande do Sul (UFRGS), Brazil
Medical School, Universidade do Vale do Rio dos Sinos (UNISINOS), Brazil

Search for other papers by Iuri Martin Goemann in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-9071-3703

Correspondence should be addressed to I M Goemann: igoemann@hcpa.edu.br
Restricted access
Rent on DeepDyve

Sign up for journal news

TERT promoter mutations C228T and C250T are associated with disease aggressiveness and poor clinical outcomes in patients with papillary thyroid carcinomas. However, very little is known about the transcriptional consequences of these mutations and whether they both carry similar oncogenic potential. Here we characterized the transcriptional disturbances and clinical outcomes associated with the presence of each of these two mutations using data derived from The Cancer Genome Atlas. We observed that tumors harboring the C228T mutation (n = 27) exhibited a 16-fold increase in TERT mRNA levels (P = 5.3 × 10−42), whereas C250T tumors (n = 8) showed only a two-fold increase in expression (P = 0.034). The C228T mutation was associated with the activation of signaling pathways controlling the cell cycle, cellular division, and extracellular matrix degradation. Univariate analysis demonstrated that the C228T mutation was associated with older age at diagnosis, large tumor size, lymph node invasion, and distant metastases at diagnosis. The C228T mutation was also associated with worse progression-free interval (PFI) in comparison to WT tumors (HR = 5,04; P < 0.001). This association remained significant in a multivariate analysis (HR = 3.74, P = 0.003) adjusting for BRAF-V600E status and ATA risk group. Our data indicate that TERT promoter mutations C228T and C250T have distinct transcriptional consequences in papillary thyroid carcinoma (PTC), suggesting a greater oncogenic potential for the C228T mutation. TERT promoter mutation C228T may be a useful prognostic marker to identify patients at high risk of distant recurrence. Clinical data for the C250T mutation is still limited, with no evidence up to date to confirm its prognostic significance.

Supplementary Materials

 

  • Collapse
  • Expand
  • Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB, et al.2014 Integrated genomic characterization of papillary thyroid carcinoma. Cell 159 676690. (https://doi.org/10.1016/j.cell.2014.09.050)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, et al.2015 Genomic classification of cutaneous melanoma. Cell 161 16811696. (https://doi.org/10.1016/j.cell.2015.05.044)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Bell RJA, Rube HT, Xavier-Magalhães A, Costa BM, Mancini A, Song JS & & Costello JF 2016 Understanding TERT promoter mutations: a common path to immortality. Molecular Cancer Research 14 315323. (https://doi.org/10.1158/1541-7786.MCR-16-0003)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al.2013 The somatic genomic landscape of glioblastoma. Cell 155 462477. (https://doi.org/10.1016/j.cell.2013.09.034)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Bullock M, Ren Y, O’Neill C, Gill A, Aniss A, Sywak M, Sidhu S, Delbridge L, Learoyd D, de Vathaire F, et al.2016 TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clinical Endocrinology 85 283290. (https://doi.org/10.1111/cen.12999)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Chen B, Shi Y, Xu Y & & Zhang J 2021 The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: a systematic review and meta-analysis. Clinical Endocrinology 94 731742. (https://doi.org/10.1111/cen.14316)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Chien M-N, Yang P-S, Hsu Y-C, Liu T-P, Lee J-J & & Cheng S-P 2018 Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation. Head and Neck 40 25282537. (https://doi.org/10.1002/hed.25385)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A & & Sancisi V 2015 TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. European Journal of Endocrinology 172 403413. (https://doi.org/10.1530/EJE-14-0837)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY & & Clayman GL 2015 Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. Journal of Clinical Endocrinology and Metabolism 100 E1550E1559. (https://doi.org/10.1210/jc.2015-2690)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al.2013 TERT promoter mutations in familial and sporadic melanoma. Science 339 959961. (https://doi.org/10.1126/science.1230062)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L & & Garraway LA 2013 Highly recurrent TERT promoter mutations in human melanoma. Science 339 957959. (https://doi.org/10.1126/science.1229259)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Kim TH, Kim Y-E, Ahn S, Kim J-Y, Ki C-S, Oh YL, Kim K, Yun JW, Park W-Y, Choe J-H, et al.2016 TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocrine-Related Cancer 23 813823. (https://doi.org/10.1530/ERC-16-0219)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA & & Fagin JA 2013 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. Journal of Clinical Endocrinology and Metabolism 98 E1562E1566. (https://doi.org/10.1210/jc.2013-2383)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Liu R & & Xing M 2016 TERT promoter mutations in thyroid cancer. Endocrine-Related Cancer 23 R143R155. (https://doi.org/10.1530/ERC-15-0533)

  • Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK & & Xing M 2013 Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 20 603610. (https://doi.org/10.1530/ERC-13-0210)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C & & Xu D 2014a The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33 49784984. (https://doi.org/10.1038/onc.2013.446)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, et al.2014b TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 99 E1130E1136. (https://doi.org/10.1210/jc.2013-4048)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Liu C, Liu Z, Chen T, Zeng W, Guo Y & & Huang T 2016 TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a meta-analysis. Scientific Reports 6 36990. (https://doi.org/10.1038/srep36990)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW & & Xing M 2017 Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncology 3 202208. (https://doi.org/10.1001/jamaoncol.2016.3288)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, et al.2014 TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 99 E754E765. (https://doi.org/10.1210/jc.2013-3734)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, Hahn S, Park DJ & & Park YJ 2017 Effects of coexistent BRAFV600E and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid 27 651660. (https://doi.org/10.1089/thy.2016.0350)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Rusinek D, Pfeifer A, Cieslicka M, Kowalska M, Pawlaczek A, Krajewska J, Szpak-Ulczok S, Tyszkiewicz T, Halczok M, Czarniecka A, et al.2020 TERT promoter mutations and their impact on gene expression profile in papillary thyroid carcinoma. Cancers 12. (https://doi.org/10.3390/cancers12061597)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Song YS, Lim JA, Choi H, Won J-K, Moon JH, Cho SW, Lee KE, Park YJ, Yi KH, Park DJ, et al.2016 Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer 122 13701379. (https://doi.org/10.1002/cncr.29934)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, et al.2013 Frequency of TERT promoter mutations in human cancers. Nature Communications 4 2185. (https://doi.org/10.1038/ncomms3185)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S & & Bishop J 2014 BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Journal of Clinical Oncology 32 27182726. (https://doi.org/10.1200/JCO.2014.55.5094)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Yang J, Gong Y, Yan S, Chen H, Qin S & & Gong R 2020 Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis. Endocrine 67 4457. (https://doi.org/10.1007/s12020-019-02117-2)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Yang H, Park H, Ryu HJ, Heo J, Kim J-S, Oh YL, Choe J-H, Kim JH, Kim JS, Jang HW, et al.2022 Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients. Endocrinology and Metabolism 37 652663. (https://doi.org/10.3803/EnM.2022.1477)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Yin DT, Yu K, Lu RQ, Li X, Xu J, Lei M, Li H, Wang Y & & Liu Z 2016 Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis. Clinical Endocrinology 85 299305. (https://doi.org/10.1111/cen.13017)

    • PubMed
    • Search Google Scholar
    • Export Citation